Palvella Therapeutics (PVLA) Liabilities and Shareholders Equity (2016 - 2024)
Historic Liabilities and Shareholders Equity for Palvella Therapeutics (PVLA) over the last 12 years, with Q3 2024 value amounting to $20.5 million.
- Palvella Therapeutics' Liabilities and Shareholders Equity fell 6543.72% to $20.5 million in Q3 2024 from the same period last year, while for Dec 2024 it was $75.1 million, marking a year-over-year decrease of 6828.82%. This contributed to the annual value of $7.5 million for FY2023, which is 9209.55% down from last year.
- According to the latest figures from Q3 2024, Palvella Therapeutics' Liabilities and Shareholders Equity is $20.5 million, which was down 6543.72% from $25.1 million recorded in Q2 2024.
- In the past 5 years, Palvella Therapeutics' Liabilities and Shareholders Equity ranged from a high of $164.2 million in Q3 2021 and a low of $7.5 million during Q4 2023
- Its 5-year average for Liabilities and Shareholders Equity is $95.2 million, with a median of $105.0 million in 2020.
- Per our database at Business Quant, Palvella Therapeutics' Liabilities and Shareholders Equity soared by 4623.37% in 2021 and then tumbled by 9209.55% in 2023.
- Palvella Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $105.0 million in 2020, then surged by 46.23% to $153.6 million in 2021, then crashed by 37.82% to $95.5 million in 2022, then crashed by 92.1% to $7.5 million in 2023, then skyrocketed by 171.89% to $20.5 million in 2024.
- Its Liabilities and Shareholders Equity was $20.5 million in Q3 2024, compared to $25.1 million in Q2 2024 and $29.5 million in Q1 2024.